ࡱ> Y[X@ !bjbjFF "4,,0@@@@@@@T   8T $x $TDh ( kCmCmCmCmCmCmC$ERGC@ C@@ C6@ @ kCkC<@@ @ r ="OCC<D=bHVbHD @TT@@@@bH@ @D |k CCTT8 pTT8 Joint Informational Hearing of the Senate Health Committee, Senate Subcommittee on Stem Cell Research Oversight, Assembly Health and Assembly Judiciary Committees Monday, October 31, 2005 Implementation of Proposition 71: Options for Handling Intellectual Property Associated with Stem Cell Research Grants Testimony of Ed Penhoet, PhD Vice Chairman, Independent Citizens Oversight Committee Chairman, IP Task Force California Institute for Regenerative Medicine October 31, 2005 As prepared My name is Ed Penhoet, and I am vice chairman of the Independent Citizens Oversight Committee (ICOC) of the California Institute for Regenerative Medicine (CIRM). I also serve as the chairman of an Intellectual Property Task Force of the ICOC. By way of background, I am currently the President of the Gordon and Betty Moore Foundation in San Francisco. Before joining the foundation, I held several positions at University of California, Berkeley including dean of the School of Public Health and professor of public health and molecular and cell biology. I am a director at Alta Partners, a pioneering venture capital firm that focuses on early-stage investing in life sciences, information technology and communications. I am also a director and co-founder of Chiron Corporation, one of the worlds leading biotechnology companies. I served as Chirons President and Chief Executive Officer from 1981 until 1998. I am delighted to be here today to let you know what the ICOC is doing in the area of developing intellectual property guidelines, and I am looking forward to hearing the testimony of your other speakers. In my statement, I will respond to the questions given to me ahead of time. What process has the ICOC established to develop Proposition 71 policies and guidelines dealing with intellectual property? The ICOC has created an Intellectual Property (IP) Task Force to review various alternatives for intellectual property created by CIRM grantees and to make recommendations to the full board of the ICOC for California Institute for Regenerative Medicine-funded grants per the requirement in the California Stem Cell Research and Cures Act [Health and Safety Code 125280.30 (h)]. The Act declares: The ICOC shall establish standards that require that all grants and loan awards be subject to intellectual property agreements that balance the opportunity of the State of California to benefit from the patents, royalties, and licenses that result from basic research, therapy development, and clinical trials with the need to assure that essential medical research is not unreasonably hindered by the intellectual property agreements. The work of the IP Task Force is broad and will include but not be limited to the following: Policy recommendations for CIRM funding conditions related to intellectual property for nonprofit institutions. Policy recommendations for CIRM funding conditions related to intellectual property for for-profit entities. Policy recommendations for potential freedom to operate agreements with parties who possess stem cell materials and patented technologies. The IP Task Force had its first meeting last week. We reviewed the recent report from the California Council on Science and Technology (CCST) that was requested by the Legislature [ACR 252 (Mullin) in 2004; ACR 24 (Mullin) in 2005] to make sure we understood their recommendations. We also heard a presentation on Californias biotechnology industry and the role that intellectual property has played in its growth. The task force also heard from representatives of patient advocacy groups, public interest groups, and the biotechnology industry who were in the audience. What is the expected timeline for the development of intellectual property policies and guidelines? The task force will continue to meet until we have a recommendation to bring forth to the full ICOC for its consideration. However, in the short term, we hope to develop an interim set of IP guidelines for a narrow area the training grants approved by the ICOC on September 9th. While training grants usually do not generate IP, we feel it is important to have something in place in the unlikely event that intellectual property is patented by one or more of the trainees. Do you have any reaction or comments on the CCSTs recent report outlining interim findings and recommendations for a Proposition 71 IP policy? The CCST interim report is a substantial document resulting from the work of a number of leaders in the state with significant experience in technology generation and/or licensing. My current task is to lead the process of developing intellectual property recommendations to the ICOC board. I strive to be objective and we will consider many different points of view in coming to a set of recommendations. In that context, I am here today to listen and observe, not to offer opinions on the CCST report or other aspects of CIRM intellectual property. Do you have any recommendations for how California can achieve an economic return on its investment of public funds in stem cell research? Our role is to spur development of new treatments and therapies science in the service of therapies in the promising area of stem cell research. To accomplish this, we recognize the importance of partnerships, especially with the private sector, to develop new tools to treat and study disease and injury. I believe that the State of California may achieve economic benefits from CIRM-funded research in a number of different ways including: Providing cures as opposed to lifelong therapies for patients Increased economic activity resulting from growth of an industry based on stem cell science: jobs, taxes, and economic development Direct remuneration to the state from arrangements with industry which provide royalties or other forms of revenue-sharing Attracting substantial increases in research and development funding to California by non-Californian entities My personal hope is that CIRM funding will leverage additional funding into stem cell research. I believe that California will have a significant impact in accelerating the development of new health technologies and healthcare treatments that will eventually reduce healthcare costs and increase the quality of life for patients and their families.     Page  PAGE 1 of  NUMPAGES 3 q7 8 T U P W !  XY$%Ľ{ h-;5h-]h-]5h7h-]h2=h. hL<h2=h|hzhPa hL<h|h-; hL<h47 hL<hU]whL<hU]w6 hv@5hL<hU]w5 hL<h@Vh@VB*OJQJ^Jph!ho5h@VB*OJQJ^Jph-# 7 8 U XY$%gd-]gd2=@&gd|gd|$a$gdv@$a$gd@V !%.2le89:89JRd 6QT#[tuwEI޿񮪮h7h7H*hhnvh7 h-]5h7h-]5h2[h2=hbh.h9h-; hL<h4Rh4R hL<hzhL<h-]6h-]hz hL<h-]>hi9:89vwFEƀ⚦gd-] & F gd4Rgd4R & F gd-]gdz & F gdz p^p`gd-]gd-]bkqy3:HIJ3Zuvw &Ci <mmprϧӧϟh>h#&h.h?h3 hL<h hL<hOI hL<hvYh hUhUh2=h9hRh7h75 h95h7h-]5h-]hUh2[hnvh7:IJvw;<qr gd#& & Fgd7 & Fgd3@&gd|gd7gd-]E _ !!h`mHnHujh@VUh@VhE#jhE#Uh2=h>h#& hL<h0 !!gd#&$a$gdL< 1h/ =!"#$%@@@ U]wNormalCJ_HaJmH sH tH DAD Default Paragraph FontRiR  Table Normal4 l4a (k(No List4@4 L<Header  !4 @4 L<Footer  !HH nv Balloon TextCJOJQJ^JaJV>@"V @VTitle&$d1$7$8$H$^a$ OJQJaJ 4#78UXY$%h i 9 : 8 9 vwIJvw;<qr000000000x000000000000X0X0X0X0X0X0X0X0X0X 0X0X 0X0X 0X0000000000000000000 0 0 0 0000@00M#7@0@0@0@0@0@0 0c  /////2%! !!*,2!8@0(  B S  ?yx: zx: } {x: .|x: }x: ~x: $$x: <6x: yx: d$x: "x: ,px: ,rx: <5"x: ,ex: ,EFFs s XXII     OSS} } bbSS V*urn:schemas-microsoft-com:office:smarttags PersonNamehttp://www.microsoft.comV *urn:schemas-microsoft-com:office:smarttagsplacehttp://www.5iantlavalamp.com/h *urn:schemas-microsoft-com:office:smarttagsCity0http://www.5iamas-microsoft-com:office:smarttagsi *urn:schemas-microsoft-com:office:smarttagsState0http://www.5iamas-microsoft-com:office:smarttags8*urn:schemas-microsoft-com:office:smarttagsdate 10200531DayMonthYear 7TU  !7TU7TUPWX Q T #[twwEHIIbbkk3:3Zmmr7TU <W nNi5 8few6 +*:j5t%$K:z nA MfP0jPY5l([n0t? },Nh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHhpp^p`OJQJ^Jo(hHoh@ @ ^@ `OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHhPP^P`OJQJ^Jo(hHoh  ^ `OJQJo(hHli5<eW j5PYfP[n nAK: +*? }M                                                                                                                              B 'l+ LB|LCYb*W  E U On E [PXh> oG g5E#N$'e'/)I);*L*Z0m1q/2:Z4FX57z8<:89:(<L<=2=b=>>Z_>i>rW^saunvU]w 6yXGywlyIEzEzfze3z012[I,/v@_h.S=l]1H`O1H3~]T1ToucW_-;6xZ`ze ?.vYR&0NG962HFHL0!c47^~yV;@_ on5%H>d+'h&/-#&YdOM'&U"!8LFrKnUVPSD$@V_#C^%ypv+NU0@k7P1}@\H'@Unknown Moe KatsimbrasGz Times New Roman5Symbol3& z Arial5& zaTahoma?5 z Courier New;Wingdings"1hOsfOsfӋ - -!4d 2qHP ?U]wTestimony of Ed Penhoet, PhDkkleinsc Moe KatsimbrasD         Oh+'0 ,8 T ` l xTestimony of Ed Penhoet, PhDest kkleinsc ofklekle Normal.dotf Moe Katsimbras2oeMicrosoft Word 10.0@F#@ vJ@bq@bq՜.+,00 hp  /California Institute for Regenerative Medicine-  Testimony of Ed Penhoet, PhD Title  !"$%&'()*+,-./0123456789:;<=>?@ABCDEFGIJKLMNOQRSTUVWZ]_^`abcdefRoot Entry FZ\@Data 1Table#HWordDocument"4SummaryInformation(HDocumentSummaryInformation8PCompObjjMsoDataStoreZZ  !"#$%&'()*+,-./012345678:;<>?@BCD  FMicrosoft Word Document MSWordDocWord.Document.89q This value indicates the number of saves or revisions. The application is responsible for updating this value after each revision. DocumentLibraryFormDocumentLibraryFormDocumentLibraryForm